Comparison of DNA and mRNA vaccines against cancer
- PMID: 31843577
- PMCID: PMC7080609
- DOI: 10.1016/j.drudis.2019.12.003
Comparison of DNA and mRNA vaccines against cancer
Abstract
Nucleic acid vaccines (NAVs) have recently been tested as a cancer therapy. DNA and mRNA vaccines deliver genetic information encoding tumor antigens (TAs) to the host, which then produces immune responses against cancer cells that express the TAs. Although NAVs are easy, safe, and simple to manufacture, they have not so far been considered viable alternatives to peptide vaccines. Choosing the right TAs, insufficient immunogenicity, and the immunosuppressive nature of cancer are some challenges to this approach. In this review, we discuss approaches that been used to improve the efficiency of anticancer NAVs.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflicts of interest
M.R.H. declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc; BeWell Global Inc.; Hologenix Inc.; LumiThera Inc.; Vielight; Bright Photomedicine; Quantum Dynamics LLC; Global Photon Inc.; Medical Coherence; NeuroThera; JOOVV Inc.; AIRx Medical; FIR Industries, Inc.; UVLRx Therapeutics; Ultralux UV Inc.; Illumiheal & Petthera; MB Lasertherapy; ARRC LED; Varuna Biomedical Corp.; and Niraxx Light Therapeutics, Inc. Consulting: Lexington Int.; USHIO Corp.; Merck KGaA; Philips Electronics Nederland; Johnson & Johnson Inc.; and Sanofi-Aventis Deutschland GmbH. Stockholdings: Global Photon Inc. and Mitonix.
Figures

References
-
- Rezaei T et al. (2019) Recent advances on HIV DNA vaccines development: stepwise improvements to clinical trials. J. Control. Release 316, 116–137 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical